US Patent grants Cellectis to cover CRISPR-Edited Allogeneic CAR T-Cells Medical Dialogues Bureau12 March 2020 3:57 PM ISTNew York: Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells...